Literature DB >> 7955493

Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity.

C Bonifati1, M Carducci, P Cordiali Fei, E Trento, G Sacerdoti, M Fazio, F Ameglio.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and granulocyte monocyte-colony stimulating factor (GM-CSF) were measured in serum and involved and uninvolved skin blister fluids of 20 psoriatic patients and 10 healthy subjects, by enzyme immunoassay. TNF-alpha and IL-6 were always detectable in involved skin blister fluids, while GM-CSF was detected only in 45% of these samples. TNF-alpha, IL-6 and GM-CSF were detected in 95, 100 and 10% of uninvolved skin blister fluid samples, respectively. TNF-alpha and IL-6 were found in 50 and 30% of control blister fluids, while GM-CSF was never detected. In serum, TNF-alpha was detected in 75% of patients and in 70% of controls; IL-6 in 45% of patients and in no controls; and GM-CSF in 35% of patients and in 20% of the controls. The median TNF-alpha and IL-6 levels in involved skin were statistically higher than those of both uninvolved and control skin blister fluids. TNF-alpha and IL-6 levels in blister fluids obtained from both involved and uninvolved skin were higher than those of the patients' sera. GM-CSF, when present in involved skin blister fluids, showed correlated levels with the other cytokines (TNF-alpha: R = 0.85, P = 0.004; IL-6: R = 0.72, P = 0.03). TNF-alpha was highly correlated with IL-6 (R = 0.78, P < 0.00001) in involved skin blister fluids. TNF-alpha and IL-6 levels of involved skin blister fluids showed significant correlations with the psoriasis area and severity index scores in the patients, suggesting a direct relationship between these cytokines and the clinical manifestations of the disease. Moreover, the TNF-alpha levels were particularly related to the erythema scores in the patients, further supporting evidence of their role in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955493     DOI: 10.1111/j.1365-2230.1994.tb02687.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  30 in total

1.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

2.  Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3.

Authors:  W L Ring; C A Riddick; J R Baker; D A Munafo; T D Bigby
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

3.  Cutaneous microdialysis: cytokine evidence for altered innate reactivity in the skin of psoriasis patients?

Authors:  Florence Sjögren; Karin Davidsson; Michael Sjöström; Chris D Anderson
Journal:  AAPS J       Date:  2012-02-29       Impact factor: 4.009

4.  Psoriasis and Sleep Apnea: A Danish Nationwide Cohort Study.

Authors:  Alexander Egeberg; Usman Khalid; Gunnar Hilmar Gislason; Lotus Mallbris; Lone Skov; Peter Riis Hansen
Journal:  J Clin Sleep Med       Date:  2016-05-15       Impact factor: 4.062

5.  Intrauterine growth restriction induces skin inflammation, increases TSLP and impairs epidermal barrier function.

Authors:  Laura Polányi; Carien M Niessen; Christina Vohlen; Julia Stinn; Tobias Kretschmer; Vanessa Jentgen; Dharmesh Hirani; Silke V Koningsbruggen-Rietschel; Jörg Dötsch; Miguel A Alejandre Alcazar
Journal:  J Mol Med (Berl)       Date:  2020-01-07       Impact factor: 4.599

Review 6.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

7.  [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].

Authors:  L Kowalzick; L Eickenscheidt; M Komar; E Schaarschmidt
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

8.  Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Authors:  A Y Goedkoop; M C Kraan; M B M Teunissen; D I Picavet; M A de Rie; J D Bos; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

9.  EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo.

Authors:  Francesca Mascia; Christophe Cataisson; Tang-Cheng Lee; David Threadgill; Valentina Mariani; Paolo Amerio; Chinmayi Chandrasekhara; Gema Souto Adeva; Giampiero Girolomoni; Stuart H Yuspa; Saveria Pastore
Journal:  J Invest Dermatol       Date:  2009-11-05       Impact factor: 8.551

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.